These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 10435912)
1. The pros and cons of genetic testing for breast and ovarian cancer risk. Frank TS; Braverman AM Int J Fertil Womens Med; 1999; 44(3):139-45. PubMed ID: 10435912 [TBL] [Abstract][Full Text] [Related]
2. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
4. [Clinical and molecular diagnosis of inherited breast-ovarian cancer]. Chompret A J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301 [TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]
6. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101 [TBL] [Abstract][Full Text] [Related]
7. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240 [TBL] [Abstract][Full Text] [Related]
8. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860 [TBL] [Abstract][Full Text] [Related]
12. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241 [TBL] [Abstract][Full Text] [Related]
13. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey. Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429 [TBL] [Abstract][Full Text] [Related]
14. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method]. Byrski T Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838 [TBL] [Abstract][Full Text] [Related]
15. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Kuschel B; Lux MP; Goecke TO; Beckmann MW Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253 [TBL] [Abstract][Full Text] [Related]
16. Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines. Beckmann MW; Schnürch HG; Bodden-Heidrich R; Mosny DS; Crombach G; Nitz U; Achnoula M; Bender HG Eur J Cancer Prev; 1996 Dec; 5(6):468-75. PubMed ID: 9061278 [TBL] [Abstract][Full Text] [Related]
17. Hereditary breast-ovarian cancer: clinical findings and medical management. Marshall M; Solomon S Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820 [TBL] [Abstract][Full Text] [Related]
18. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605 [TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Osorio A; Barroso A; Martínez B; Cebrián A; San Román JM; Lobo F; Robledo M; Benítez J Br J Cancer; 2000 Apr; 82(7):1266-70. PubMed ID: 10755399 [TBL] [Abstract][Full Text] [Related]
20. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. Forman AD; Hall MJ Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]